Sudden Hearing Loss: What the AAO-HNS 2019 Guideline Says About HBOT
The 2019 AAO-HNS guideline lists HBOT with steroids as an option for sudden sensorineural hearing loss, but only within specific time windows and as a may-offer recommendation.
A time-sensitive emergency of the ear
Sudden sensorineural hearing loss is a rapid, usually one-sided drop in hearing that develops over hours to a few days, often with no identifiable cause. It is treated as an urgent condition because outcomes depend heavily on how quickly treatment begins. Corticosteroids are the mainstay, and hyperbaric oxygen therapy has been studied as an addition rather than a replacement.
The guideline emphasizes that this is a distinct diagnosis that should be confirmed rather than assumed. It recommends distinguishing sensorineural loss from a conductive cause, and it advises evaluation, such as with an audiogram and appropriate imaging, to rule out other causes before or alongside treatment. That diagnostic step is what makes the treatment options, including HBOT, relevant to the right patients.
The most authoritative reference in this area is the clinical practice guideline from the American Academy of Otolaryngology - Head and Neck Surgery, updated in 2019.
What the guideline recommends
The 2019 guideline addresses HBOT directly and includes it as an option in two specific windows. Clinicians may offer, or refer to someone who can offer, hyperbaric oxygen therapy combined with steroid therapy within two weeks of the onset of sudden sensorineural hearing loss. It also states that clinicians may offer HBOT combined with steroids as salvage therapy within one month of onset, meaning when initial treatment has not produced full recovery.
The wording matters. These are may offer recommendations, which sit below a strong recommendation. The guideline presents HBOT as a reasonable option to discuss, not as a standard step that every patient should receive.
How strong is the benefit
The evidence behind the recommendation suggests that some patients, particularly those with more severe or profound hearing loss, may see greater improvement in hearing thresholds when HBOT is added within the time window. But the benefit is not universal, effect sizes vary across studies, and the guideline frames it as an option precisely because the certainty is moderate rather than high.
It is also worth understanding what the option is weighed against. The guideline positions HBOT alongside, not instead of, corticosteroid treatment, and it discourages certain other interventions that lack good evidence. Presenting HBOT as a lone miracle step misreads a guideline that treats it as one considered choice among a structured set of options.
The recurring theme is timing. The earlier treatment starts within these windows, the more relevant the option becomes, which is why prompt assessment by an ear specialist matters more than any single therapy choice.
A note on chamber type
It is worth being precise about equipment here. The protocols studied for sudden hearing loss use clinical pressures typical of hard-shell hyperbaric chambers, which is a different category from the low-pressure soft-sided systems described at soft-sided chambers. Those milder devices are not what the guideline evidence is based on, and conflating the two can be misleading.
Sudden hearing loss needs urgent professional assessment. Whether HBOT is added, and within which window, is a decision for an otolaryngologist coordinating your care, not something to arrange independently.